Helping stroke and dementia patients live longer may not be as complicated as it sounds. When doctors focus on the risk factors for stroke and dementia, fewer die or need expensive long-term care.

An experimental medication designed to protect the heart from injury during coronary artery bypass surgery does not appear to reduce serious complications including stroke or dying.

Clot-busting drug tissue plasminogen activator ( tPA ) is the only approved treatment for dissolving blood clots common during stroke, heart attacks or pulmonary embolisms.

Doctors have known that heart attack patients are at an increased risk of a future heart event, but the reason has been elusive. Now they think they know what causes that increased risk of recurrence.

Emergency room patients who suffer an unexplained bout of atrial fibrillation, a common heart arrhythmia, appear to be at a very low risk of long-term complications.

After a stroke, tPA (tissue plasminogen activator), also known as a clot buster, offers the most effective acute treatment.

Statins  used to lower cholesterol appear to reduce the number of heart events suffered in both men and women. However, such medications were not found to reduce stroke or death in women.

United States Food and Drug Administration officials today delayed approval of Eliquis ( apixaban ) to prevent stroke or systemic embolism in patients with a common heart arrhythmia for the second time.

For most patients with a heart rhythm disorder called atrial fibrillation, a procedure that uses electrical currents can successfully restore a normal heart rhythm.

There is a lot of evidence suggesting that coronary heart disease is linked to psychological distress symptoms like anxiety and depression. However, it may be that heart disease is not the only risk.